Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

PHASE4RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2029

Conditions
Non-Traumatic Subarachnoid Hemorrhage
Interventions
DRUG

Metoprolol

"Metoprolol Dosing:~Metoprolol Injection (instructions: 5mg, once) Metoprolol Tab (25mg PO, q12 hours, timed to start 1hr after Metoprolol Injection, 6 doses) If unable to take PO medication, Metoprolol Injection (instructions, 5mg q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"

DRUG

Placebo

"Placebo Dosing:~Placebo Injection (instructions: 5mL NS, once) Placebo Tab (1 tab PO, q12 hours, timed to start 1hr after placebo injection, 6 doses) If unable to take PO medication, Placebo Injection (instructions, 5mL q6hrs for 12 doses) Continue for 72-hours of administration unless reaching stopping criteria"

Trial Locations (1)

04012

RECRUITING

MaineHealth, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MaineHealth

OTHER

lead

Madeleine Puissant

OTHER

NCT06569212 - Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS) | Biotech Hunter | Biotech Hunter